Evidence map›Paper›PMID 34834526›Full record

ArticleJournal of personalized medicine2021

Use of Drug Claims Data and a Medication Risk Score to Assess the Impact of CYP2D6 Drug Interactions among Opioid Users on Healthcare Costs.

Veronique Michaud, Ravil Bikmetov, Matt K Smith, Pamela Dow, Lucy I Darakjian, Malavika Deodhar, Brian Cicali, Kevin T Bain, Jacques Turgeon

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. A systematic review of real-world evidence on the clinical relevance, characterization, and utility ofJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025
    Pooled it
  2. Article
  3. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Expert opinion on drug metabolism & toxicology · 2022
    Review
  4. Review
  5. Illustrative and historic cases of phenoconversion.American journal of translational research · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Veronique MichaudTabula Rasa HealthCare (TRHC), Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA.
Ravil BikmetovTabula Rasa HealthCare (TRHC), Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA.
Matt K SmithTabula Rasa HealthCare (TRHC), Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA.ORCID 0000-0003-3919-3404
Pamela DowTabula Rasa HealthCare (TRHC), Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA.ORCID 0000-0002-9983-8545
Lucy I DarakjianTabula Rasa HealthCare (TRHC), Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA.
Malavika DeodharTabula Rasa HealthCare (TRHC), Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA.ORCID 0000-0002-1661-6518
Brian CicaliCenter for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32611, USA.ORCID 0000-0002-7932-8599
Kevin T BainBiophilia Partners, Philadelphia, PA 19103, USA.ORCID 0000-0002-5009-4848
Jacques TurgeonTabula Rasa HealthCare (TRHC), Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA.ORCID 0000-0002-7978-9280
Research & Development Institute · USUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytochrome P450 2D6 (CYP2D6) activity is highly variable due to several factors, including genetic polymorphisms and drug-drug-gene interactions. Hydrocodone, oxycodone, codeine, and tramadol the most commonly prescribed CYP2D6-activated opioids for pain. However, the co-administration of CYP2D6 interacting drugs can modulate CYP2D6-medicated activation of these opioids, affecting drug analgesia, effectiveness, and safety, and can impact healthcare costs. A retrospective, observational cohort analysis was performed in a large (

Indexed as

CYP2D6drug-drug interactionsmedical expendituremedication risk scoreopioidspharmacoeconomics

Identifiers

PMID34834526
PMCPMC8622634
OpenAlexW3214653923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.